Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Refractory Pediatric Autoimmune Diseases
ChiCTR2600123400Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teclistamab in systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), Sjögren's syndrome and 1 more, sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence and characteristics of adverse events. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
teclistamab
03
Conditions
systemic lupus erythematosus (SLE)juvenile dermatomyositis (JDM)Sjögren's syndromesystemic sclerosis (SSc)
Beyond the preview
Go deeper on ChiCTR2600123400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123400.